Kerry Wentworth Sells 36,750 Shares of Nuvation Bio (NYSE:NUVB) Stock

Nuvation Bio Inc. (NYSE:NUVB) insider Kerry Wentworth sold 36,750 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $5.01, for a total transaction of $184,117.50. Following the transaction, the insider directly owned 53,000 shares of the company’s stock, valued at approximately $265,530. This trade represents a 40.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kerry Wentworth also recently made the following trade(s):

• On Monday, April 6th, Kerry Wentworth sold 200,000 shares of Nuvation Bio stock. The stock was sold at an average price of $4.52, for a total transaction of $904,000.00.

Nuvation Bio Trading Up 0.3%

Shares of Nuvation Bio stock opened at $5.12 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.95 and a quick ratio of 6.81. The firm has a fifty day moving average price of $4.85 and a 200 day moving average price of $5.86. Nuvation Bio Inc. has a 1 year low of $1.57 and a 1 year high of $9.75. The stock has a market cap of $1.78 billion, a PE ratio of -8.54 and a beta of 1.60.

Nuvation Bio (NYSE:NUVB) last issued its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. The firm had revenue of $41.87 million during the quarter, compared to analysts’ expectations of $36.82 million. Equities research analysts predict that Nuvation Bio Inc. will post -0.47 earnings per share for the current year.

Wall Street Analyst Weigh In

NUVB has been the subject of several recent research reports. Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Nuvation Bio in a report on Thursday, April 16th. Royal Bank Of Canada raised their target price on shares of Nuvation Bio from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Tuesday, March 3rd. HC Wainwright reduced their target price on shares of Nuvation Bio from $18.00 to $17.00 and set a “buy” rating for the company in a report on Monday, January 12th. UBS Group reduced their target price on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, March 3rd. Finally, Truist Financial set a $13.00 target price on shares of Nuvation Bio in a report on Tuesday, January 27th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Nuvation Bio currently has an average rating of “Moderate Buy” and a consensus target price of $11.63.

Institutional Trading of Nuvation Bio

Several institutional investors have recently modified their holdings of NUVB. Rangeley Capital LLC purchased a new position in Nuvation Bio in the 2nd quarter valued at about $25,000. Parallel Advisors LLC lifted its stake in Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after buying an additional 2,597 shares in the last quarter. Cetera Investment Advisers purchased a new position in Nuvation Bio in the 2nd quarter valued at about $29,000. Captrust Financial Advisors purchased a new position in Nuvation Bio in the 2nd quarter valued at about $32,000. Finally, Swiss Life Asset Management Ltd purchased a new position in Nuvation Bio in the 3rd quarter valued at about $39,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Key Headlines Impacting Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Longer‑term pooled data from the pivotal TRUST‑I and TRUST‑II trials presented at AACR showed very durable responses (median DOR ~50 months), strong PFS (~46 months in TKI‑naïve patients), high overall response rates and robust intracranial activity — a clear clinical catalyst that can materially support valuation if regulatory / commercial paths remain favorable. Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses…
• Positive Sentiment: Investor coverage and positive growth metrics are getting attention — media pieces note the stock has more than doubled year‑on‑year and institutional buying has increased, which can attract momentum investors. Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year
• Positive Sentiment: Pipeline upside: analysis highlights potential glioma revenue opportunity for Nuvation’s programs — a successful expansion into CNS tumors would materially broaden peak sales assumptions. Nuvation Bio Inc (NUVB): Take a Look at Glioma Revenue Potential
• Positive Sentiment: Buy‑side visibility: Nuvation appears on recent hedge‑fund / small‑cap biotech watchlists and several funds have increased positions, signaling institutional interest that can support near‑term demand. 5 Best Small-Cap Biotech Stocks to Buy According to Hedge Funds
• Neutral Sentiment: Options flow shows traders are pricing a potentially large near‑term move (higher open interest/volume), which increases implied volatility and could amplify price swings in either direction. This is a volatility signal rather than directional proof. Are options traders betting on a big move in Nuvation Bio stock?
• Negative Sentiment: Insider selling: two executives sold large blocks (e.g., Kerry Wentworth sold 36,750 shares; Dongfang Liu sold 50,000 shares) under pre‑arranged 10b5‑1 plans — reduces insider stake and can be perceived negatively despite being routine. Nuvation Bio (NYSE:NUVB) Insider Kerry Wentworth Sells 36,750 Shares

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.